



BRIEF-Neurotrope Announces Strategic Partnership With BryoLogyx

June 10, 2020 6:53 AM

June 10 (Reuters) - Neurotrope Inc:

* NEUROTROPE ANNOUNCES STRATEGIC PARTNERSHIP WITH BRYOLOGYX FOR SUPPLY OF SYNTHETIC BRYOSTATIN-1 AND CONTINUATION OF THE NATIONAL CANCER INSTITUTE (NCI) TRIAL FOR CHILDHOOD LEUKEMIA

* NEUROTROPE - UNDER TERMS, BRYOLOGYX WILL SUPPLY CO WITH SPECIFIED AMOUNTS OF SYNTHETIC, GMP-GRADE BRYOSTATIN-1., MANUFACTURED BY AMRI GROUP

* NEUROTROPE - BRYOLOGYX WILL PAY FEE ON GROSS REVENUES GENERATED BY COMMERCIAL SALE OF BRYOSTATIN-1 PRODUCT SOLD BY BRYOLOGYX

About BryoLogyx

BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents. The company's initial focus is on cancer, where it capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development. BryoLogyx has exclusive rights from Stanford University to the method's use in the areas of cancer and HIV. Bryostatin, currently in development for use with immuno-oncology agents, has an established safety profile based on clinical studies involving more than 1100 patients. Learn more at www.bryologyx.com

Contacts

Peter Steinerman

Steinerman Biomedical

Tel: 516-641-8959

Email: prsteinerman@gmail.com